Sarepta Therapeutics | SRPT - 流动负债



金融业
股票价格
USD
资产
USD 3.18B
现金及等价物
USD 464.45M
销售成本
USD 109.46M
流动资产
USD 2.31B
流动负债
USD 499.16M
债务
USD 1.04B
EBIT
USD 358.43M
EBITDA
USD -252.2M
员工
1.37K
EPS每股收益
USD 3.16
股本和储备
USD 1.51B
销售毛利
USD 621.34M
债务利息支出
USD 20.84M
利息收入
USD 8.74M
贷款资金
USD 838.16M
市值
USD 1.59B
净收入
USD 330.96M
营业费用
USD 372.37M
营业利润
USD 358.43M
普通股股本
USD 105.57M
PE价格收益
27.27
税前利润
USD 343.17M
销售收入
USD 730.8M
销售和管理费用
USD 54.03M
股票
USD 1B
贸易债权人
USD 70.38M
应收帐款人
USD 547.91M


流动负债 更改 日
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Capricor Therapeutics USD 33.64M 2.2M 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novavax USD 342.46M 117.49M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03